ArticleClinical cancer research : an official journal of the American Association for Cancer Research2020
Metastatic Breast Cancer: TIL it is Too Late.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Revealing the Interactions of Regulatory Factors in the Immune Microenvironment of Breast Cancer Based on Two-Way Orthogonal Partial Least Square Model and Cell Communication.Cancer medicine · 2026Article
- Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms.Oncogene · 2025Review
- Branched glycopolymer prodrug-derived nanoassembly combined with a STING agonist activates an immuno-supportive status to boost anti-PD-L1 antibody therapy.Acta pharmaceutica Sinica. B · 2024Article
- [JAG1 affects monocytes-macrophages to reshape the pre-metastatic niche of triple-negative breast cancer through LncRNA MALAT1 in exosomes].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2023Article
- Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Where Are We Now and Where Are We Headed?Current treatment options in oncology · 2023Review
- Spatial immunophenotypes orchestrate prognosis in triple-negative breast cancer with Miller-Payne grade 4 following neoadjuvant chemotherapy.NPJ breast cancer · 2023Article
- Immunotherapy for Metastatic Triple Negative Breast Cancer: Current Paradigm and Future Approaches.Current treatment options in oncology · 2023Review
- Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer.Frontiers in immunology · 2023Article
- Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response.Signal transduction and targeted therapy · 2022Review
- STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer.Nature communications · 2022Article
- Pathogenesis of Triple-Negative Breast Cancer.Annual review of pathology · 2022Review
- Formosanin C promotes the curative efficacy of ultrasound-guided radiofrequency ablation in a mouse model of breast cancer.Oncology letters · 2021Article
- Upregulation of HIF1-α via an NF-κB/COX2 pathway confers proliferative dominance of HER2-negative ductal carcinoma in situ cells in response to inflammatory stimuli.Neoplasia (New York, N.Y.) · 2020Article
Corrections and comments
- Commented on by
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paired analysis of primary and metastatic triple-negative breast cancers shows that metastatic disease is an immunodepleted state. This understanding has important implications for targeting the immune microenvironment in breast cancer, placing a greater emphasis on earlier stage disease and shaping future treatment strategies in the metastatic setting.
Indexed as
Identifiers
31792035What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.